AbbVie’s Mavyret receives FDA approval for treatment of hepatitis C
by Press Release from Outbreak News Today on (#2YAVX)
The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir)to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also approved for adult patients with HCV genotype 1 infection who have been ["]
The post AbbVie's Mavyret receives FDA approval for treatment of hepatitis C appeared first on Outbreak News Today.